Survivorship and Quality of Life in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Jayram how the concept of survivorship has become an increasingly important consideration in the management of metastatic castration sensitive prostate cancer (mCSPC). Dr. Jayram explains that as treatment advances have extended survival, clinicians must now think beyond short term disease control and consider the long term impact of therapy on patients’ daily functioning and overall well being. He highlights that many individuals with mCSPC remain on treatment for several years, making preservation of physical function, independence, and quality of life essential components of clinical decision making. The discussion also emphasizes the importance of selecting therapies that balance efficacy with tolerability, particularly for patients who may already have significant comorbidities. Dr. Jayram notes that careful monitoring and ongoing communication with patients are critical to ensure that treatment strategies support both disease management and sustained quality of life throughout the course of metastatic castration sensitive prostate cancer.